Rani Therapeutics Holdings, Inc.
RANI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.64 | -0.01 | 0.76 |
| FCF Yield | -91.67% | -61.96% | -34.25% | -10.16% |
| EV / EBITDA | -1.29 | -1.67 | -2.36 | -3.93 |
| Quality | ||||
| ROIC | -302.68% | -119.01% | -60.37% | -42.48% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 0.63 | 1.51 | 0.73 | 3.87 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | 40.53% |
| Free Cash Flow Growth | 31.83% | -9.00% | -46.97% | -102.67% |
| Safety | ||||
| Net Debt / EBITDA | -0.51 | -0.37 | -0.05 | 2.26 |
| Interest Coverage | -10.59 | -13.00 | -59.24 | -110.73 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 151.96 | -287.74 | -406.17 | 0.00 |